2021CCS / CHFS《心力衰竭指南更新: 定义新的射血分数降低心力衰竭治疗的药理学标准》解读

2021-11-01 四川省医学科学院医药导报

2021 年 4 月，加拿大心血管学会( CCS) 和加拿大心力衰竭学会( CHFS) 联合发布了《心力衰竭指南更新: 定义新的射血分数降低心力衰竭治疗的药理学标准》，为HFrEF患者的药理学管理建议

中文标题：

发布机构：

四川省医学科学院

发布日期：

2021-11-01

简要介绍：

自 2017 年全面更新的加拿大心血管学会 ( Canadian Cardiovascular Society，CCS) 和加拿大心力衰竭学会( Canadian Heart Failure Society，CHFS) 心力衰竭( 心衰) 管理指南以来，出现了大量与射血分数降低的心力衰竭( heart failure with reduced ejection fraction，HFrEF) 患者治疗相关的新证据。

2021 年 4 月发布的《CCS / CHFS 心衰指南更新: 定义新的射血分数降低心力衰竭治疗的药理学标准》( 以下简称指南) 在现有证据的基础上定义了 HFrEF 患者的最新治疗标准，包括血管紧张肽受体-脑啡肽酶抑制药( angiotensin receptor-neprilysin inhibitor，ARNI) 、窦房结抑制药、钠葡萄糖转运蛋白 2( sodium glucose transport 2，SGLT2) 抑制药和可溶性鸟苷酸环化酶( soluble guanylate cyclase， sGC) 激动药，以及成熟的和传统的 HFrEF 治疗。本指南更新范围仅限于针对 HFrEF 患者的关键药物治疗。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=006091c0022e7177, title=2021CCS / CHFS《心力衰竭指南更新: 定义新的射血分数降低心力衰竭治疗的药理学标准》解读, enTitle=, guiderFrom=医药导报, authorId=0, author=, summary=2021 年 4 月，加拿大心血管学会( CCS) 和加拿大心力衰竭学会( CHFS) 联合发布了《心力衰竭指南更新: 定义新的射血分数降低心力衰竭治疗的药理学标准》，为HFrEF患者的药理学管理建议, cover=https://img.medsci.cn/20211129/1638196140645_5579292.png, journalId=0, articlesId=null, associationId=2170, associationName=四川省医学科学院, associationIntro=四川省医学科学院, copyright=0, guiderPublishedTime=Mon Nov 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="page" title="Page 1"> <div class="layoutArea"> <div class="column"> <p>自 2017 年全面更新的加拿大心血管学会 ( Canadian Cardiovascular Society，CCS) 和加拿大心力衰竭学会( Canadian Heart Failure Society，CHFS) 心力衰竭( 心衰) 管理指南以来，出现了大量与射血分数降低的心力衰竭( heart failure with reduced ejection fraction，HFrEF) 患者治疗相关的新证据。</p> <div class="page" title="Page 1"> <div class="layoutArea"> <div class="column"> <p>2021 年 4 月发布的《CCS / CHFS 心衰指南更新: 定义新的射血分数降低心力衰竭治疗的药理学标准》( 以下简称指南) 在现有证据的基础上定义了 HFrEF 患者的最新治疗标准，包括血管紧张肽受体-脑啡肽酶抑制药( angiotensin receptor-neprilysin inhibitor，ARNI) 、窦房结抑制药、钠葡萄糖转运蛋白 2( sodium glucose transport 2，SGLT2) 抑制药和可溶性鸟苷酸环化酶( soluble guanylate cyclase， sGC) 激动药，以及成熟的和传统的 HFrEF 治疗。本指南更新范围仅限于针对 HFrEF 患者的关键药物治疗。</p> </div> </div> </div> </div> </div> </div>, tagList=[TagDto(tagId=335, tagName=心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2149, appHits=298, showAppHits=0, pcHits=511, showPcHits=1849, likes=1, shares=22, comments=4, approvalStatus=1, publishedTime=Tue Nov 30 09:59:41 CST 2021, publishedTimeString=2021-11-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Nov 29 22:29:03 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 08:41:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_2021CCS_CHFS《心力衰竭指南更新_定义新的射血分数降低心力衰竭治疗的药理学标准》解读.pdf)])

_2021CCS_CHFS《心力衰竭指南更新_定义新的射血分数降低心力衰竭治疗的药理学标准》解读.pdf

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1077210, encodeId=bc8810e721086, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83cc5593421, createdName=燕子111, createdTime=Mon Dec 06 01:55:55 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076526, encodeId=094a10e6526de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f15574968, createdName=ms3000000884115523, createdTime=Fri Dec 03 11:59:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075910, encodeId=108a10e5910c5, content=学会了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Wed Dec 01 16:56:11 CST 2021, time=2021-12-01, status=1, ipAttribution=)]
2021-12-06 燕子111

学习

54 0
[GetPortalCommentsPageByObjectIdResponse(id=1077210, encodeId=bc8810e721086, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83cc5593421, createdName=燕子111, createdTime=Mon Dec 06 01:55:55 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076526, encodeId=094a10e6526de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f15574968, createdName=ms3000000884115523, createdTime=Fri Dec 03 11:59:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075910, encodeId=108a10e5910c5, content=学会了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Wed Dec 01 16:56:11 CST 2021, time=2021-12-01, status=1, ipAttribution=)]
2021-12-03 ms3000000884115523

学习了

51 0
[GetPortalCommentsPageByObjectIdResponse(id=1077210, encodeId=bc8810e721086, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83cc5593421, createdName=燕子111, createdTime=Mon Dec 06 01:55:55 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076526, encodeId=094a10e6526de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f15574968, createdName=ms3000000884115523, createdTime=Fri Dec 03 11:59:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075910, encodeId=108a10e5910c5, content=学会了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Wed Dec 01 16:56:11 CST 2021, time=2021-12-01, status=1, ipAttribution=)]
2021-12-01 ms8000002131364081

学会了

55 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2021CCS / CHFS《心力衰竭指南更新: 定义新的射血分数降低心力衰竭治疗的药理学标准》解读

相关指南

科室

工具

服务